Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6273903 | 0.99 | LMNA (0.39) | SMN1; SMN2LMNATHRATHRBGAA | |
| SCHEMBL10942288 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATHRATHRBGAA | |
| SCHEMBL10949964 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATHRATHRBGAA | |
| SCHEMBL10949604 | 0.89 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNATHRATHRBGAA | |
| SCHEMBL10943626 | 0.88 | LMNA (0.39) | SMN1; SMN2LMNATHRATHRBGAA | |
| SCHEMBL10943623 | 0.81 | CTSB (0.48) | SMN1; SMN2LMNAGAAMAPTCTSB | |
| SCHEMBL10945856 | 0.81 | CTSB (0.48) | SMN1; SMN2LMNAGAAMAPTCTSB | |
| SCHEMBL10942788 | 0.81 | CTSB (0.48) | SMN1; SMN2LMNAGAAMAPTCTSB | |
| SCHEMBL4785005 | 0.81 | TXNRD1 (0.35) | SMN1; SMN2LMNATXNRD1GSRESR1 | |
| SCHEMBL4726606 | 0.80 | LMNA (0.35) | SMN1; SMN2LMNAGAAMAPTTXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4727233-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| JP-2006521284-A | — | — | 2006-09-21 | — | — | JP | claimed |
| US-6979740-B2 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2005-12-27 | — | — | US | claimed |
| EP-1606263-A1 | RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS | Council of Scientific and Industrial Research (IN) | 2005-12-21 | — | — | EP | claimed |
| WO-2004085402-A1 | RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-07 | — | — | WO | claimed |
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) | 2004-09-30 | — | — | US | claimed |
| US-6979740-B2 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2005-12-27 | — | — | US | disclosed |
| EP-1606263-A1 | RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS | Council of Scientific and Industrial Research (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004085402-A1 | RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | QDPR, SLC11A2, CYP2C8 | SMN1; SMN2 4098/4885LMNA 1368/4885THRA 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.